134 related articles for article (PubMed ID: 31412114)
1. Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy.
Feagins LA; Kim J; Chandrakumaran A; Gandle C; Naik KH; Cipher DJ; Hou JK; Yao MD; Gaidos JKJ
Inflamm Bowel Dis; 2020 Apr; 26(5):728-733. PubMed ID: 31412114
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease.
Lischalk JW; Blacksburg S; Mendez C; Repka M; Sanchez A; Carpenter T; Witten M; Garbus JE; Evans A; Collins SP; Katz A; Haas J
Radiat Oncol; 2021 Jul; 16(1):126. PubMed ID: 34243797
[TBL] [Abstract][Full Text] [Related]
3. Implications of Prostate Cancer Treatment in Men With Inflammatory Bowel Disease.
Kirk PS; Govani S; Borza T; Hollenbeck BK; Davis J; Shumway D; Waljee AK; Skolarus TA
Urology; 2017 Jun; 104():131-136. PubMed ID: 28163082
[TBL] [Abstract][Full Text] [Related]
4. Short-term Toxicity of High Dose Rate Brachytherapy in Prostate Cancer Patients with Inflammatory Bowel Disease.
Mohammed W; Hoskin P; Henry A; Gomez-Iturriaga A; Robinson A; Nikapota A
Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):534-538. PubMed ID: 30099986
[TBL] [Abstract][Full Text] [Related]
5. Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease.
Pai HH; Keyes M; Morris WJ; Christie J
Brachytherapy; 2013; 12(2):126-33. PubMed ID: 22738665
[TBL] [Abstract][Full Text] [Related]
6. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease.
Peters CA; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):424-9. PubMed ID: 16887295
[TBL] [Abstract][Full Text] [Related]
7. Managing Patients with Inflammatory Bowel Disease Who Develop Prostate Cancer.
Kim J; Feagins LA
Dig Dis Sci; 2020 Jan; 65(1):22-30. PubMed ID: 31713121
[TBL] [Abstract][Full Text] [Related]
8. Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques.
Murphy CT; Heller S; Ruth K; Buyyounouski MK; Weinberg D; Uzzo RG; Plimack E; Kutikov A; Chen DYT; Horwitz EM
Pract Radiat Oncol; 2015; 5(3):e215-e222. PubMed ID: 25424586
[TBL] [Abstract][Full Text] [Related]
9. Prostate brachytherapy in patients with inflammatory bowel disease.
Grann A; Wallner K
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):135-8. PubMed ID: 9422569
[TBL] [Abstract][Full Text] [Related]
10. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
11. Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy.
White EC; Murphy JD; Chang DT; Koong AC
Am J Clin Oncol; 2015 Dec; 38(6):564-9. PubMed ID: 24401668
[TBL] [Abstract][Full Text] [Related]
12. Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma.
Buckstein M; Kerns S; Forysthe K; Stone NN; Stock RG
BJU Int; 2013 Mar; 111(3 Pt B):E43-7. PubMed ID: 23046084
[TBL] [Abstract][Full Text] [Related]
13. Hospitalizations for Acute Myocardial Infarction Are Decreased Among Patients with Inflammatory Bowel Disease Using a Nationwide Inpatient Database.
Barnes EL; Beery RM; Schulman AR; McCarthy EP; Korzenik JR; Winter RW
Inflamm Bowel Dis; 2016 Sep; 22(9):2229-37. PubMed ID: 27542135
[TBL] [Abstract][Full Text] [Related]
14. Potency after permanent prostate brachytherapy for localized prostate cancer.
Potters L; Torre T; Fearn PA; Leibel SA; Kattan MW
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1235-42. PubMed ID: 11483334
[TBL] [Abstract][Full Text] [Related]
15. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
[TBL] [Abstract][Full Text] [Related]
16. Prognosis after first-time myocardial infarction in patients with inflammatory bowel disease according to disease activity: nationwide cohort study.
Kristensen SL; Ahlehoff O; Lindhardsen J; Erichsen R; Lamberts M; Khalid U; Nielsen OH; Torp-Pedersen C; Gislason GH; Hansen PR
Circ Cardiovasc Qual Outcomes; 2014 Nov; 7(6):857-62. PubMed ID: 25316773
[TBL] [Abstract][Full Text] [Related]
17. Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease.
Siva S; Rubin DT; Gulotta G; Wroblewski K; Pekow J
Inflamm Bowel Dis; 2017 Jan; 23(1):152-157. PubMed ID: 27930412
[TBL] [Abstract][Full Text] [Related]
18. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature.
Budäus L; Bolla M; Bossi A; Cozzarini C; Crook J; Widmark A; Wiegel T
Eur Urol; 2012 Jan; 61(1):112-27. PubMed ID: 22001105
[TBL] [Abstract][Full Text] [Related]
19. A Matched Case-Control Analysis of Clinical Outcomes for Patients With Inflammatory Bowel Disease and Rectal Cancer Treated With Pelvic Radiation Therapy.
Mudgway R; Bryant AK; Heide ES; Riviere P; O'Hare C; Rose BS; Murphy JD; Simpson DR
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):994-1004. PubMed ID: 31461672
[TBL] [Abstract][Full Text] [Related]
20. Clinical factors to predict flare-up in patients with inflammatory bowel disease during international air travel: A prospective study.
Park J; Yoon H; Shin CM; Park YS; Kim N; Lee DH
PLoS One; 2022; 17(1):e0262571. PubMed ID: 35061808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
